Results 1 to 10 of about 1,927 (159)
Drug-drug interactions with raltegravir
European Journal of Medical Research, 2009 Objective To review all currently published drug-drug interaction studies with the HIV-integrase inhibitor raltegravir. Methods A PubMed search was conducted for all published reports up to August 1, 2009 as well as a review of updated European and US ...
Burger David M
doaj +7 more sources
Raltegravir in treatment naïve patients [PDF]
European Journal of Medical Research, 2009 Raltegravir is the first integrase inhibitor approved for the treatment of HIV infection based on the superior efficacy it showed compared to optimized backbone therapy alone in patients harboring multidrug resistant viruses.
Cossarini F, Castagna A, Lazzarin A
doaj +5 more sources
New therapeutic strategies for raltegravir [PDF]
Journal of Antimicrobial Chemotherapy, 2009 Raltegravir (Isentress) is the first approved HIV integrase inhibitor. Agents in this class target a different viral enzyme compared with agents inhibiting reverse transcriptase and protease. A wide number of patients are currently susceptible to integrase inhibitors, including heavily antiretroviral-experienced patients harbouring drug-resistant ...
Carmen Garrido +2 more
openalex +4 more sources
Raltegravir use in special populations [PDF]
European Journal of Medical Research, 2009 Raltegravir, the first approved integrase inhibitor, has been shown to be virologically effective in Phase II and Phase III clinical trials in both treatment naive and triple class resistant patients. It also has an excellent tolerability profile and lacks significant drug-drug interactions making it an important drug in the treatment of a number of ...
Margaret Johnson
openalex +5 more sources
Acta Crystallographica Section E, 2013 The hydrated title compound [systematic name: N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-{1-methyl-1-[(5-methyl-1,3,4-oxadiazol-2-ylcarbonyl)amino]ethyl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide monohydrate], C20H21FN6O5·H2O, is recognised as the ...
H. S. Yathirajan +4 more
doaj +4 more sources
Clinical Epidemiology, 2010 Frederik N Engsig1, Jan Gerstoft1, Gitte Kronborg2, Carsten S Larsen3, Gitte Pedersen4, Anne M Audelin5, Louise B Jørgensen5, Niels Obel11Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Denmark; 2Department ...
Frederik N Engsig +3 more
doaj +3 more sources
High levels of polymorphisms related to raltegravir resistance among raltegravir‐naïve individuals in Brazil [PDF]
Journal of the International AIDS Society, 2010 7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow ...
Nathalia Mantovani +4 more
openalex +3 more sources
Adverse events of raltegravir and dolutegravir [PDF]
AIDS, 2017 To compare the frequency and risk factors of toxicity-related treatment discontinuations between raltegravir and dolutegravir.Prospective cohort study.All antiretroviral therapy (ART)-naïve and ART-experienced HIV-infected individuals from the Swiss HIV Cohort Study who initiated raltegravir or dolutegravir between 2006 and 2015 were investigated ...
Elzi, Luigia +8 more
openaire +8 more sources
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. [PDF]
PLoS ONE, 2009 Raltegravir is an HIV-1 integrase inhibitor currently used in treatment-experienced HIV-1-infected patients resistant to other drug classes. In order to assess its central nervous system penetration, we measured raltegravir concentrations in ...
Aylin Yilmaz +6 more
doaj +1 more source
Reduction of the HIV protease inhibitor-induced ER stress and inflammatory response by raltegravir in macrophages. [PDF]
PLoS ONE, 2014 HIV protease inhibitor (PI), the core component of highly active antiretroviral treatment (HAART) for HIV infection, has been implicated in HAART-associated cardiovascular complications.
Xiaoxuan Zhang +11 more
doaj +1 more source